Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting

Figure 2

Forest plot of the arthralgia incidence in patients receiving CDK4/6 inhibitors plus ET versus ET alone.